Ondine Biomedical (LSE:OBI) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 12, 2026)


LSE:OBI Ondine Biomedical Inc LSE:OBI
28 GF Score
Price £0.15
GF Value £0.10
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Ondine Biomedical Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Ondine Biomedical's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LSE:OBI vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Ondine Biomedical's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ondine Biomedical Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ondine Biomedical's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Ondine Biomedical's Margin of Safety % (DCF Earnings Based) falls into.


LSE:OBI
28GF Score
Ondine Biomedical Inc LSE:OBI
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ondine Biomedical (LSE:OBI) Overvalued in 2026?

Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued. The current stock price of £0.15 is trading 45% above its estimated GF Value™ of £0.10. GuruFocus considers Ondine Biomedical to be Significantly Overvalued.

Key valuation signals for LSE:OBI:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: £0.10 vs. price of £0.15 (45% above fair value)
  • GF Score™: 28/100 with 9 warning signs

No single metric tells the full story. See the LSE:OBI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ondine Biomedical Business Description

Other Exchanges OBIMF:USAVF5:Germany
Address 1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
28GF Score

Get the complete analysis for LSE:OBI

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.15
Price
£0.10
GF Value